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Background: Bipolar disorder (BPD) is prevalent and is associated with a significant economic burden. Asenapine,
the first tetracyclic antipsychotic approved in Canada for the treatment of BPD, has shown a comparable efficacy
profile to other atypical antipsychotics. In addition, it is associated with a favourable metabolic profile and minimal
weight gain potential. This study aimed to assess the economic impact of asenapine compared to olanzapine in
the treatment of BPD in Canada.
Methods: A decision tree combined with a Markov model was constructed to assess the cost-utility of asenapine
compared with olanzapine. The decision tree takes into account the occurrence of extrapyramidal symptoms (EPS),
the probability of switching to a different antipsychotic, and the probability of gaining weight. The Markov model
takes into account long-term metabolic complications including diabetes, hypertension, coronary heart diseases
(CHDs), and stroke. Analyses were conducted from both a Canadian Ministry of Health (MoH) and a societal
perspective over a five-year time horizon with yearly cycles.
Results: In the treatment of BPD, asenapine is a dominant strategy over olanzapine from both a MoH and a
societal perspective. In fact, asenapine is associated with lower costs and more quality-adjusted life years (QALYs).
Results of the probabilistic sensitivity analysis indicated that asenapine remains a dominant strategy in 99.2% of the
simulations, in both a MoH and a societal perspective, and this result is robust to the many deterministic sensitivity
analyses performed.
Conclusions: This economic evaluation demonstrates that asenapine is a cost-effective strategy compared to
olanzapine in the treatment of BPD in Canada.
Keywords: Asenapine, Bipolar disorder, Antipsychotic, Canada, Cost-utility, Cost-effectiveness, OlanzapineBackground
Bipolar disorder (BPD), also known as manic-depressive
disorders, is a chronic mood disorder. BPD type I is the
classical syndrome, whereas BPD type II is characterized
by more major depressive episodes [1–3]. Mental Health
and Well-Being survey estimated the lifetime prevalence
rate for BPD in Canada at 2.2%, which means that over
500,000 Canadians suffer from this condition [4]. In
addition, the prevalence of suicide is high in the BPD
population, with a lifetime prevalence of suicide attempts
at up to 30% in 1996 in an American context [5].
Because BPD is one of the leading causes of disability,
especially in active populations, it imposes a substantial* Correspondence: Jean.lachaine@umontreal.ca
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reproduction in any medium, provided the oreconomic burden on society [6]. An analysis of US
epidemiological data collected between 1991 and 2009
estimated the direct and indirect costs of BPD I and II
disorder at $US30.7 and $US120.3 billion, respectively, for
a total economic burden of $US151.0 billion. From a
European perspective, the estimated UK national cost
of BPD disorder was £4.59 billion in 2007 pounds
(about $US7.5 billion), with hospitalization during acute
episodes accounting for the largest component of direct
costs [7]. Moreover, BPD may also cause distress for
caregivers and family members [8].
Mood stabilizers such as lithium, valproate, and
carbamazepine are crucial in the treatment of BPD,
however, the efficacy and tolerability of these agents is often
inadequate, requiring the addition of other medications [3].
Atypical antipsychotics have shown efficacy in mania andal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mood stabilizers, but are associated with substantial weight
gain and metabolic changes, including extrapyramidal side
effects (EPS) [9,10]. In addition to the significant impact
of weight gain on quality of life and utility, the metabolic
effects associated with atypical antipsychotics increase the
risk of developing long-term complications. Furthermore,
metabolic effects may constitute one of the many factors
that contribute to medication nonadherence in patients
with BPD.
To date, few economic evaluations have focused on
the use of atypical antipsychotics in the treatment of
BPD. Most economic evaluations concerning BPD were
cost-effectiveness analysis, with the number of acute mood
episodes avoided as the primary clinical outcome. Those
economic evaluations have largely been based on Markov
models, where treatment discontinuation or switches were
taken into account [11–15]. To date, the use of asenapine
for treating BPD has not been evaluated in Canada from
an economic standpoint. Therefore, the objective of this
study was to assess the economic impact of asenapine
compared with olanzapine in the treatment of BPD over a
5-year time horizon.
Method
For this economic evaluation, a model based cost-utility
analysis was performed. For the base-case analysis,
asenapine was compared to olanzapine because it has
been used as the comparator in pivotal clinical trials
[16–19]. In addition, olanzapine is one of the most
commonly prescribed atypical antipsychotic drugs in
Canada for BPD. The patient population presented
the characteristics of patients in pivotal clinical trials
of asenapine in BPD (moderate to severe BPD, onset
at age of 40 years) [16–19]. To encompass short-term
and long-term outcomes and the costs associated with
atypical antipsychotic use, this economic evaluation was
conducted over a five-year time horizon. In addition, a
ten-year time-horizon was considered in a complementary
analysis. Given the low adherence to antipsychotic
medications in BPD patients, a longer perspective was
not considered [20].
Model structure
A decision tree combined with a time-dependent
Markov model was constructed to assess the cost-
effectiveness of asenapine compared with olanzapine in
the treatment of BPD (Figure 1). A focus was placed
on weight gain and long-term metabolic complications
associated with treatments. According to expert clinicians
(psychiatrists from the Douglas Mental Health University
Institute, Montreal, Quebec), this model structure was
clinically meaningful for accurate representation of disease
evolution and treatment.First, a decision tree with a one-year time horizon
was constructed to take into account the occurrence
of EPS-related events, the probability of switching
treatment, and the probability of gaining weight. A
proportion of patients who experienced EPS discontinued
their first treatment and switched to another. The treatment
used when a treatment switch occurred was aripiprazole, as
it is the most recently approved atypical antipsychotic
for schizophrenia (SCZ) and BPD indications, with similar
metabolic properties to asenapine. Moreover, according to
clinical experts, aripiprazole was considered the most
appropriate option in case of treatment switch. Weight
gain was considered according to results of pivotal clinical
trials, where patients tend to significantly gain weight
(≥7%) within the first year of treatment [16–19].
A Markov model was developed for the subsequent years
of treatment. Markov health states included long-term
metabolic complications such as diabetes, hypertension,
CHDs, and stroke associated with weight gain, and
the absorbing health state was death. According to the
prevalence of each complication at age 40, as reported for
the overall population, a proportion of BPD patients who
entered the Markov model were already suffering from
metabolic complications. Thereafter, patients progressed in
the model health states with the reported annual incidence
rate for each complication, taking into account the elevated
risks for patients with weight gain associated with their
BPD treatment. Diabetes and hypertension are chronic
diseases and stroke and CHDs are punctual events with
chronic consequences. Then, they were included in the
model once the condition occurred, and they remained
until death. It was assumed that complications could occur
at any time during the horizon of the Markov model. In
addition, although patients could acquire more than one
complication during the model time period, it was
assumed that only one complication could occur per
patient per year. Further details on transition probabilities
of the Markov model are available in Additional file 1.
Clinical data
For the base-case scenario, the incidence rates of
EPS-related adverse effects and of significant weight
gain (≥7%) with asenapine and olanzapine were taken
from pivotal clinical trials that directly compared the
two treatments (Table 1) [16–19]. The proportion of
treatment switch due to an EPS-related event in patients
who experienced an EPS was assumed to be the same as
that estimated in SCZ from clinical trials comparing
asenapine and olanzapine because no data was available in
BPD clinical trials [35]. A ≥7% weight gain was considered
significant, according to data reported in pivotal asenapine
clinical trials [16–19]. Moreover, the 7% weight gain is one
of the clinical meaningful cuts used in most BPD clinical
trials, and is recognized by the National Institute for
Figure 1 Model structure.
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ately capture weight gain complications, incidence data
was taken from a study reporting on weight gain incidence
after 52 weeks of antipsychotic treatment [19]. Because
the EPS-related events occur early after treatment
initiation, all pivotal studies, including short duration
study, which reported a proportion of patients who
experienced an EPS-related event, were considered.
Because data for the BPD population specifically was
not available, the risks for selected complications in the
general population who gained weight were extracted.
The risks of developing long-term complications according
to metabolic changes were extracted from the literature
(Table 1). In studies that presented weight gain measures
other than a ≥ 7% increase (weight gained (kg), body mass
index change, etc.), the risk corresponding to the most
conservative significant weight gain was applied. In fact,
according to the average weight observed in BPD clinical
trials, [16–19] an increase of at least 5 kg corresponds to a
7% increase of initial body weight.
Costs data
All costs are expressed in Canadian dollar 2011 value. All
costs estimated before 2011 were adjusted to June 2011
levels based on the health component of the Canadian
Consumer Price Index [40].
The costs included in the analysis from a Ministry of
health (MoH) perspective were those associated withmedication, EPS management and healthcare resources
used in the management of metabolic complications
(Table 2). The cost of Saphris® was provided by Lundbeck
Canada Inc., and the costs of the other antipsychotics were
taken from the Liste des médicaments (list of medications)
provided by the Régie de l’assurance maladie du Québec
(RAMQ, Quebec’s health insurance board) [41]. For
olanzapine, costs differ across dosages as well as manufac-
turers. Therefore, the RAMQ database was used to estimate
the mean cost of olanzapine, based on its use in a real-life
setting. First, patients with a diagnosis of BPD (International
Classification of Diseases, ICD9 296.0-296.9) and who had a
valid prescription for any dose and any brand of olanzapine
on February 1, 2011 were identified. A mean daily cost was
then estimated by multiplying the number of tablets used
per day by the unit cost of olanzapine. For aripiprazole used
in cases of treatment switch, the unit cost in the Liste des
médicaments was directly multiplied by the number of
tablets recommended daily, because it is commercialized
under the original brand only and all available doses are the
same price. According to expert clinicians as well as
the Canadian guidelines, management of EPS-related
symptoms would require one extra physician visit, as
these symptoms can usually be attenuated by reducing
the dosage or switching the medication [48]. The costs
associated with metabolic complications were those
covered by the MoH, including medical costs (physician,
outpatient care, emergency visits, hospitalizations, and
Table 1 Model inputs: clinical parameters
Base-case Lower bound Upper bound
Target population [16–19]
Age at onset 40 20 N/A
Incidence of adverse effects [18]
Significant weight gain
Asenapine 39.2% 29.4% 49.0%
Olanzapine 55.1% 41.3% 68.9%
EPS-related event
Asenapine 10.7% 7.2% 14.9%
Olanzapine 9.5% 6.8% 13.1%
Risks of developing complications (OR)
Men Women Men Women Men Women
Diabetes [21,22] 2.69 1.9 2.17 1.5 3.34 2.3
Hypertension [23,24] 1.68 1.56 1.45 1.48 1.94 1.64
CHDs [22,25] 1.68 1.25 1.13 1.01 2.5 1.55
Stroke [26] 1.02 1.02 1.01 1.01 1.03 1.03
Mortality risks Men Women Men Women Men Women
Diabetes [27] 1.88 1.88 1.55 1.55 2.27 2.27
Hypertension [28] 1.44 1.34 1.00 1.00 2.88 2.68
CHDs [29,30] 2.20 1.60 2.00 1.20 2.40 2.10
Stroke [31] 2.37 2.37 2.11 2.07 2.64 2.70
Utilities/Disutilities
Disease-related [32]
BPD 0.800 0.580 1.000
Weight gain in BPD −0.066 −0.050 −0.083
EPS in BPD −0.074 −0.090 −0.053
Weight of additional disutilities 0 0.5 1.0
Complications [33] Men Women Men Women Men Women
Type II diabetes −0.06 −0.05 −0.08 −0.08 −0.03 −0.03
Hypertension −0.02 0 −0.03 −0.02 0 0.01
CHDs (Heart disease) −0.07 −0.06 −0.09 −0.08 −0.05 −0.03
Effects of stroke −0.17 −0.18 −0.23 −0.25 −0.12 −0.10
Suicide rate [34] 15.50 12.25 18.44
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with a complication were estimated using data from
pharmaceutical and medical services retrieved from
Quebec’s Provincial Health Plan database. The RAMQ
data are anonymized and are publicly available, at a
cost, for research purposes. The RAMQ Direction
for analysis and management of information manage
the distribution of RAMQ data to external parties.
More specifically, for each complication, the differ-
ence between the median annual costs incurred by
patients aged from 40 to 44 years who had the com-
plication from January 1, 2003 to December 31, 2009
and the median annual costs incurred by patients in
the same age range who did not have the complication
was calculated.For the analysis using a societal perspective, additional
costs associated with loss of productivity and informal
care due to long-term metabolic complications were also
considered (Table 2). Costs associated with productivity
losses were obtained from Canadian public sources
[28,43–46]. The estimated overall productivity loss for a
complication was divided by the prevalence of the compli-
cation in the overall Canadian population in the estimated
year to obtain the cost per patient. When prevalence data
for the year of estimation were unavailable, the prevalence
in the nearest available year was used. In the literature,
only patients with stroke have been reported to require
significant home care [49]. In fact, based on a Canadian
study by Goeree et al., caregiver expenses account for 12%
of the total one-year stroke cost, which amounts to
Table 2 Model inputs: costs
Event cost ($)
Base-case Lower bound Upper bound
Treatment Costs
Cost of annual treatment
Asenapine 1,030.00 N/A N/A
Olanzapine [41] 1,871.00 1,316.00 2,426.00
-Cost of EPS management [42] 60.00 0.00 N/A
Costs associated with long-term metabolic complications
Direct costs*
Diabetes 3,834.77 1,215.00 17,072.00
Hypertension 571.00 233.00 827.00
CHDs
Fatal CHDs 7,093.20 775.00 52,617.00
CHDs (Year 1) 2,481.24 818.00 8,819.00
CHDs (Year 2–5) 1,146.11 360.00 5,795.00
Stroke
Fatal stroke 30,776.93 7,362.00 34,165.00
Stroke (Year 1) 4,034.86 1,395.00 10,560.00
Stroke (Year 2–5) 1,867.59 452.00 8,692.00
Productivity losses [28,43–46]
Diabetes 528.00 396.00 660.00
Hypertension 119.00 89.25 148.75
CHDs 3,109.00 2,331.75 3,886.25
Stroke 4,322.00 3,241.50 5,402.50
Informal care [47]
Stroke 3,770.00 2,827.50 4,712.50
*Estimated from the RAMQ database.
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in the present economic evaluation, only informal care
associated with stroke was considered.
Utility
Utilities associated with BPD and disutilities associated
with EPS and metabolic complications were taken into
account in this analysis (Table 1). Revicki and colleagues
used the standard gamble method to estimate the utilities
for BPD [32]. They found that BPD was associated with a
mean utility of 0.80. They also found that weight gain was
associated with a 0.066 decrease in utility. Because the
disutilities associated with EPS were unavailable for BPD,
it was assumed that the disutility associated with EPS in
BPD was similar to that for SCZ. Therefore, a 0.074 mean
reduction in utility for acute EPS events, as reported in
Lenert et al.’s SCZ study, was included in the model [50].
Disutilities associated with weight gain and EPS were
subtracted from the baseline utility observed in BPD
patients [39]. EPS-associated disutility was estimated
to last for three months, whereas it was permanent in
the case of weight gain.Long-term metabolic complications of interest are also
associated with a significant reduction in utility. Schultz
and Kopec estimated the impact of various self-reported
chronic conditions on health-related quality of life, as
measured by the Health Utilities Index 3 [33]. According to
their results, the mean disutility values for each metabolic
complication included in the model were taken into
account. (Table 1) When more than one complication
was present concomitantly, the disutility of only the
most debilitating complication was considered in the
base-case analysis. Taking into account baseline utility for
BPD, these disutility values were used to adjust the
number of quality-adjusted life years (QALYs) according
to development of long-term metabolic complications.
Mortality
Survival rates were taken from the most recent Canadian
life tables available for men and women for the general
population [51]. Because BPD patients present higher
suicide rates than the general population, mortality rates
of the general population were adjusted by suicide rates
reported in BPD patients. According to a meta-analysis
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a BPD population compared to the general population
(Table 1) [34]. To incorporate the higher risk of suicide
associated with BPD in the model, the estimated mortality
due to suicide in the general Canadian population for
men and women at 40 years was first subtracted from
the mortality observed in the general population [52].
The higher risk of suicide in the BPD population was
then added.
The risks of mortality associated with complications of
interest were also taken into account (Table 1). In the
case of several concomitant complications, all mortality
risks were included for the base-case scenario. The risk
of mortality caused by fatal stroke or CHD events
(mostly myocardial infarction) were also included. Fatal
cases of stroke and CHD events were estimated using
the RAMQ database.Analyses
The incremental cost-utility ratios (ICURs) were calcu-
lated as the total cost associated with asenapine treat-
ment minus the total cost associated with olanzapine
treatment divided by the number of QALYs associated
with asenapine minus the number of QALYs associated
with olanzapine. Consistent with the Canadian Agency for
Drugs and Technologies in Health recommendations, costs
and benefits were discounted at a rate of 5% per year.
A complementary analysis using a ten-year time hori-
zon was performed to assess the impact of metabolic
complications over a longer period.
Robustness of the results of this analysis was tested
by deterministic and probabilistic sensitivity analyses.
Confidence intervals were used as lower and upper
bounds when available. When confidence intervals
were not available, a ±25% variation was applied to
the base-case parameters (Table 1). Deterministic analyses
were performed by varying individually within lower
and upper bounds the gender distribution, starting
age, incidence of adverse effects, risks of developing
selected long-term metabolic complications, mortality
risks, costs, utilities, and suicide and discount rates.
Probabilistic sensitivity analyses were conducted using
Monte Carlo simulation by varying simultaneously base-
line characteristics, clinical outcomes, resource utilization
and cost parameter inputs. The probabilistic analysis
was undertaken by randomly sampling each parameter
distributions and calculating the expected costs and
expected number of QALYs for that combination of
parameter values for a total of 10,000 replications.
Probabilistic sensitivity analysis was performed using
Oracle Crystal Ball version 11.1.1.1.00 to assess the
overall impact of uncertainty associated with the study
parameters on the base-case results.Results
Base-case analysis
Over a five-year time period, asenapine was found to be a
dominant strategy over olanzapine in the treatment of
BPD, from both a MoH and a societal perspective (Table 3).
Thus, the costs associated with the use of asenapine are
lower than those associated with the use of olanzapine, and
the number of QALYs obtained with asenapine is higher
than the number obtained with olanzapine. Per 1,000
patients, there was a gain of 84.84 QALY with the use of
asenapine and a decrease in cost of Can$3,847,300 from a
MoH perspective and a decrease of Can$3,878,343 from
a societal perspective.
Complementary analyses
From both MoH and societal perspectives, asenapine
remained a dominant alternative over a ten-year time
horizon (Table 3).
Sensitivity analysis
Results of the deterministic and probabilistic analyses
confirmed the robustness of the base-case results.
According to the deterministic analysis results, asenapine
remained a dominant strategy from both perspectives.
The individual variation of each parameter had no impact
on the base-case results. The probabilistic sensitivity
analysis also confirmed the robustness of the base-case
results. From both a MoH and a societal perspective,
asenapine was a dominant alternative over olanzapine
in 99.2% of the Monte Carlo simulations.
Discussion
This economic evaluation suggests that, compared with
olanzapine, asenapine is a dominant alternative from both
a MoH and a societal perspective. Asenapine is associated
with a lower treatment cost and a lower risk of gaining
weight (39.2% vs. 55.1%, respectively) than olanzapine,
which leads to a lower risk of developing metabolic
complications. Moreover, the results of the exhaustive
sensitivity analysis confirmed the robustness of the
base-case results.
This is the first Canadian economic evaluation of asena-
pine in the treatment of BPD. To date, few studies have
assessed the economic impact of atypical antipsychotics
with a focus on metabolic changes and their complications
on quality of life and survival in SCZ and BPD context. For
example, in a recent study by McIntyre et al., a semi-Markov
model was constructed to evaluate the cost and predicted
incidence of long-term complications (type-2 diabetes,
angina, myocardial infarction, stroke, and cardiovascular-
related deaths) associated with metabolic changes induced
by treatment with atypical antipsychotic agents in SCZ
[53]. More recently, Kasteng et al. developed a Markov
health state transition model and found that treatment
Table 3 ICURs – base-case scenario and ten-year time horizon scenario / 1,000 individuals
Costs ($) Incremental costs ($) QALYs Incremental QALYs ICUR ($/QALY)
MoH perspective
Base-case scenario
Olanzapine 9,729,158 −3,847,300 3,301 84.84 dominant
Asenapine (Saphris®) 5,881,858 3,386
Ten-year time horizon scenario
Olanzapine 18,233,001 −6,956,705 5,784 160.67 dominant
Asenapine (Saphris®) 11,276,296 5,945
Societal perspective
Base-case scenario
Olanzapine 11,466,846 −3,878,343 3,301 84.84 dominant
Asenapine (Saphris®) 7,588,702 3,386
Ten-year time horizon scenario
Olanzapine 22,527,000 −7,131,099 5,784 160.67 dominant
Asenapine (Saphris®) 15,395,901 5,945
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in the treatment of SCZ and BPD, with 0.08 QALYs gained
and cost savings of $US4,000 per patient over a lifetime
horizon [15]. However, this study has some limitations,
including the lack of consideration of non-metabolic
adverse events and drug switching or discontinuation.
This economic evaluation has several strengths. First,
the type of analysis chosen, a cost-utility analysis, allows
considering atypical antipsychotic-related metabolic
effects on mortality and morbidity. In addition, the
analysis accounted for adverse events associated with
treatment, including EPS and weight gain as well as
treatment switches due to EPS. Furthermore, because
weight gain is a progressive adverse effect, the choice of a
one-year period for weight gain development better
reflects the reality. Pharmaceutical and medical services
were taken from a RAMQ database to estimate the costs
of metabolic complications based on real-life settings. The
RAMQ database was also used to accurately estimate the
cost of antipsychotics used by BPD patients in real-life
settings. Because different doses of antipsychotics are used
for different indications, estimates of treatment costs in
real-life settings, and specifically in a BPD population,
constituted the most appropriate method.
However, this economic evaluation has several limi-
tations. First, despite the limited clinical data on atypical
antipsychotics in the treatment of BPD, there was suf-
ficient evidence to develop an economic evaluation
comparing asenapine to olanzapine specifically for this
indication. However, there was insufficient evidence to
support an economic evaluation comparing asenapine to
other atypical antipsychotics. In addition, because certain
data on BPD patients were unavailable, some model
parameters, such as disutility associated with EPS and
risks of developing complications, were obtained in SCZpatients and general population respectively. Moreover,
given the absence of direct comparison between asenapine
and olanzapine in clinical trials of antipsychotics used as
combination therapy, this economic evaluation focused
solely on a comparison of these agents as monotherapy
for BPD.
Then, as for any model-based analysis, many assumptions
were made, which may increase the uncertainty of the
results. However, a conservative approach was adopted
to define each model assumption. For example, in the
base-case analysis, the disutility of only one complication
was taken into account, even when patients had more
than one complication. In addition, the time horizon was
limited to five years, although the benefits of reducing
weight gain can extend beyond that period. However, the
impact of a 10-year time horizon was assessed in the
complementary analyses. Moreover, the development of
complications was limited to only one per cycle, although
some patients may develop more than one complication
in the same year. Furthermore, the model allows for only
one treatment switch, although several switches may be
required before obtaining the optimal treatment in
terms of efficacy and safety. A further limitation of
this analysis is the assumption that patients remained
on their medication continuously for five years, even
though studies have reported significant nonadherence
rates to antipsychotic treatment across BPD populations
[54,55]. However, lack of treatment persistence was observed
across all atypical antipsychotic agents. Therefore, the
predicted clinical and economic benefits with asenapine
would apply for the proportion of BPD patients who would
persist with their pharmacological regimen. In addition, this
persistence assumption has been applied both to asenapine
and olanzapine. Moreover, the model assumed that
metabolic complications are independent consequences of
Lachaine et al. BMC Psychiatry 2014, 14:16 Page 8 of 9
http://www.biomedcentral.com/1471-244X/14/16weight gain. More specifically, the model included increased
risks of metabolic complications due to weight gain, but did
not take into account the impact of existing comorbidities
on the development of new complications. For example,
literature reported that people with type II diabetes have a
risk of CHD 2–4 times greater than the general population
[56,57]. However, people suffering from diabetes often
presents other factors that could also be associated with the
incidence of CHD. It is highly probable that there is
a synergy between these factors and complications. It
becomes difficult to isolate the risk of developing
CHD associated with the combination of diabetes and
weight gain. On the other hand, the addition of these
risks would probably lead to an overestimation of the risk of
developing CHD. Therefore, the risks of developing CHD
and diabetes associated with weight gain were considered
separately, as the model focuses on the metabolic effects
associated with antipsychotic use. The choice of including
the risk of developing CHD when suffering from diabetes
would possibly lead to a more favourable cost-effectiveness
ratio for asenapine. However, when increasing the risk of
developing CHD in sensitivity analyses, asenapine remains a
dominant strategy over olanzapine. The assumption of
considering metabolic complications as independent
outcomes was therefore conservative. Furthermore, the
model did not allow for potential dosage reduction associ-
ated with EPS occurrence. In any case, this would have a
minimal impact on the overall result, considering the rela-
tively low incidence of EPS that requires dose adjustment in
current practice. Despite these limitations, findings of this
analysis are robust according to sensitivity analyses.Conclusion
In conclusion, this economic evaluation showed that
asenapine is a dominant alternative over olanzapine in
the treatment of BPD.Additional file
Additional file 1: Transition rates for the Markov model. This table
provides the probability of developing each complication (hypertension,
diabetes, CHD, stroke, fatal MI, fatal stroke) during the 5-year horizon time
of the Markov model.Abbreviations
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